Selective Laser Trabeculoplasty versus Eye Drops for First-Line Treatment of Ocular Hypertension and Glaucoma (LiGHT): A Multicentre Randomised Controlled Trial

AI Generated Summary*

In the LiGHT trial, 718 untreated adults with ocular hypertension or open angle glaucoma were randomised at six UK hospitals to initial selective laser trabeculoplasty (n=356) or pressure-lowering drops (n=362), with masked measurements and treat-to-target escalation over 36 months. The primary outcome, EQ-5D health-related quality of life, did not differ significantly (0.89 versus 0.90; p=0.23). Among laser-treated patients, 74.2% needed no drops at three years, eyes met target pressure at 93.0% of visits versus 91.3%, and no eye needed glaucoma surgery compared with 11 in the drops arm. Ophthalmology costs were £451 lower per patient, with a 97% probability of cost-effectiveness at £20,000 per QALY (68% including non-eye costs). The investigators conclude laser should be offered first-line.

*This summary was generated by AI and is published unedited. Oku does not alter these summaries. It may contain errors or omissions and is provided for general informational purposes only. Oku does not guarantee its accuracy, completeness, or reliability. For authoritative information, please refer to the original, peer-reviewed article.